20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Gainers

• Cellect Biotechnology, Inc. APOP shares moved upwards by 212.5% to $7.50 during Tuesday's pre-market session.
• Apellis Pharmaceuticals, Inc. APLS shares surged 55.9% to $47.05. The most recent rating by Bank of America, on December 19, is at Buy, with a price target of $36.00.
• Tyme Technologies, Inc. TYME shares moved upwards by 52.6% to $2.35.
• Xeris Pharmaceuticals, Inc. XERS shares surged 21.2% to $7.02.
• Tonix Pharmaceuticals, Inc. TNXP shares increased by 16.8% to $1.81.
• Hepion Pharmaceuticals, Inc. HEPA stock surged 15.8% to $6.08. The most recent rating by Brookline Capital, on November 22, is at Buy, with a price target of $12.00.
• Lipocine, Inc. LPCN shares surged 13.9% to $0.48.
• VIVUS, Inc. VVUS shares moved upwards by 13.3% to $3.06.
• Viveve Medical, Inc. VIVE stock rose 8.9% to $1.10. According to the most recent rating by Ladenburg Thalmann, on December 03, the current rating is at Buy.
• Sophiris Bio, Inc. SPHS shares increased by 7.7% to $0.84.
• Microbot Medical, Inc. MBOT shares surged 3.0% to $12.20. The most recent rating by H.C. Wainwright, on December 24, is at Buy, with a price target of $12.00.
• Savara, Inc. SVRA stock rose 2.3% to $3.55.
• Onconova Therapeutics, Inc. ONTX shares increased by 2.2% to $0.48.
• Titan Pharmaceuticals, Inc. TTNP stock moved upwards by 1.7% to $0.30. The most recent rating by Maxim Group, on October 23, is at Buy, with a price target of $1.00.
• IVERIC bio, Inc. ISEE stock moved upwards by 1.6% to $8.25.
• Exelixis, Inc. EXEL shares rose 1.6% to $17.83. The most recent rating by Guggenheim, on October 15, is at Buy, with a price target of $25.00.

Losers

• Cassava Sciences, Inc. SAVA stock declined 7.1% to $8.02 during Tuesday's pre-market session.
• Guardion Health Sciences, Inc. GHSI stock decreased by 4.8% to $0.37.
• Alexion Pharmaceuticals, Inc. ALXN stock declined 3.6% to $102.76. According to the most recent rating by Morgan Stanley, on December 17, the current rating is at Equal-Weight.
• Ocugen, Inc. OCGN shares declined 2.6% to $0.67. According to the most recent rating by H.C. Wainwright, on December 20, the current rating is at Buy.